profit from every $100 of sales.
$0$100
Axsome Therapeutics
$140.97+5.23% today
+2.3% in 1 year
1-year low $129.801-year high $255.17
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Axsome Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $50.0 million in 2022 to $638 million in 2025, with -$183 million of profit last year.
SalesProfit
Axsome Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Axsome Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Axsome Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | – | 50 | 271 | 386 | 638 | |
| – | – | 45 | 245 | 352 | 591 | |
| -99 | -125 | -177 | -183 | -252 | -169 | |
| -99 | -125 | -175 | -225 | -273 | -168 | |
| -103 | -130 | -187 | -239 | -287 | -183 | |
| -2.77 | -3.47 | -4.60 | -5.27 | -5.99 | -3.68 | |
| – | – | 89.6% | 90.4% | 91.4% | 92.6% | |
| – | – | -352.7% | -67.6% | -65.5% | -26.5% | |
| – | – | -374.0% | -88.4% | -74.5% | -28.7% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 186 | 88 | 331 | 588 | 568 | 690 |
| Cash | 184 | 86 | 201 | 386 | 315 | 323 |
| Total debt | 50 | 50 | 95 | 186 | 193 | 218 |
| Total liabilities | 72 | 72 | 222 | 397 | 511 | 602 |
| 114 | 16 | 110 | 191 | 57 | 88 | |
| 37 | 38 | 41 | 45 | 48 | 50 | |
| -47.8% | -150.8% | -69.5% | -48.5% | -88.7% | -45.7% | |
| -90.4% | -834.3% | -170.8% | -125.3% | -503.8% | -207.5% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -78 | -108 | -117 | -145 | -128 | -93 | |
| 0 | 0 | 1 | 1 | 0 | 0 | |
| -79 | -109 | -117 | -146 | -129 | -94 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 15 | 21 | 38 | 63 | 85 | 94 |
Valuation
- –
- –
- –
- 213.6×
- 11.6×
- –
- –
- -1.3%
- -2.5%
- 0.0%
Profitability
- 92.6%
- -26.5%
- -28.7%
- -24.4%
- -50.8%
- -105.0%
- -260.0%
- -26.4%
- -64.0%
- 27.0%
Growth
- +133.7%
- –
- +27.0%
- –
- +7.2%
Financial health
- -0.6×
- 3.97
- 30.4%
- -33.1×
- 1.39
- 1.32
- 0.99
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 7%of 953
Bottom 10%of 877
Top 4%of 871
Bottom 33%of 988
What analysts expect
- Average price target
- $241.25
- Range
- $200.00 – $281.00
- 18 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 4, 2026 | -1.26 | -0.85 | −48.2% |
| Feb 23, 2026 | -0.71 | -0.70 | −1.4% |
| Nov 3, 2025 | -0.94 | -0.82 | −14.6% |
| Aug 4, 2025 | -0.92 | -1.00 | +8.0% |
| May 5, 2025 | -0.80 | -1.26 | +36.5% |
| Feb 18, 2025 | -0.96 | -1.00 | +4.0% |
| Nov 12, 2024 | -1.34 | -1.38 | +2.9% |
| Aug 5, 2024 | -1.24 | -1.30 | +4.6% |
News
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?Yahoo Finance · Sep 18, 2026Is Axsome Therapeutics a Buy on the Dip?Yahoo Finance · Sep 18, 2026Axsome rises on Auvelity prescription dataSeeking Alpha · Sep 11, 2026Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to RunYahoo Finance · Aug 23, 2026The newest story we have is from Sep 18, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
13No pass
Philip Fisher
44No pass
Peter Lynch
2No pass
Joel Greenblatt
2No pass
Charlie Munger
26No pass
Terry Smith
24No pass
Questions about Axsome Therapeutics
Is Axsome Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Axsome Therapeutics AI analysis
What does Axsome Therapeutics do?
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. It is in Biotechnology, based in New York, NY, United States, with 1,220 employees.
Does Axsome Therapeutics pay a dividend?
No. Axsome Therapeutics does not pay a dividend at the moment.
Is Axsome Therapeutics stock halal?
Yes. Axsome Therapeutics passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Axsome Therapeutics stock done over the past year?
Up 2.3% over the past twelve months, to $140.97. It traded between $129.80 and $255.17 and is 44.8% below its high.
Who are Axsome Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Axsome Therapeutics's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.